Scientific Programme

The decision has been reached to postpone the meeting originally planned for 2020 to a date to be confirmed. The programme below reflects the original programme which we will be working with the faculty and Committees to ensure is current for the new dates once these are confirmed. Should you have any questions or comments, please do not hesitate to get in touch with us at: [email protected]

Day One

09.00–10.30Pre-Congress Workshops and Educational Sessions

Session 1Gaps and challenges in Latin America
Session co-ordinated by the Latin American HIV Workshop Group

Session 2Improving Patient Outcomes Through Better Management of DDIs
Session co-ordinated by Fundación Huésped and the University of Liverpool

Session 3Clinical trial workshop
Session co-ordinated by CICAL, Buenos Aires

10.30–11.00Coffee, Scientific Posters and Exhibition

11.00–11.15Official Opening
Mauro Schechter and Pedro Cahn

11.15–11.45Keynote Lecture: What Will it Take to End the Epidemic: The Global Perspective
Wafaa El Sadr, I
CAP at Columbia University, New York, NY, USA

11.45–12.15Keynote Lecture: New Drugs: New Formulations and Delivery Mechanism
and Systems for HIV

Ethel D Weld, Johns Hopkins University School of Medicine, Baltimore, MD, USA


12.30–14.00Gilead Industry Symposium


14.15–16.00Current Controversies in Dual Therapy/INSTIs

14.15–14.30INSTIs in Latin America: where are we?
Ricardo Diaz, Infectious Diseases Department, Paulista School of Medicine,
Federal University of São Paulo, São Paulo, Brazil

14.30–14.45INSTI-based dual therapy: what have we learned, what do we still ignore?
Pedro Cahn, Huésped Foundation, Buenos Aires, Argentina

14.45–15.00The heavy issue: INSTIs and weight gain
Francois Venter, Wits Reproductive Health and HIV Institute at the University
of the Witwatersrand, Johannesburg, South Africa

15.00–15.15INSTI-based dual therapy in patients with unknown baseline resistance
Daniel Kuritzkes, Harvard Medical School and Division of Infectious
Diseases, Brigham and Women’s Hospital, Boston, MA, USA

15.15–15.25Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral
treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI
studies in Latin American participants

Norma Porteiro, Infectious Diseases, Fundacion IDEAA, Buenos Aires, Argentina

15.25–15.35Alarming Levels of resistance to antiretroviral drugs in key and
vulnerable populations

Samuel Pierre, Les Centres, GHESKIO, Port-au-Prince, Haiti

15.35–16.00Panel discussion 

16.00–16.30Coffee, Scientific Posters and Exhibition

16.30–18.00Co-morbidities/Elderly population/Cancers

16.30–16.45End-stage renal disease in HIV patients: options and challenges

16.45–17.00Dermatological manifestations in HIV patients
Eduardo Rodriguez, Buenos Aires, Argentina

17.00–17.15HIV and ageing: current issues in Latin America
Yanink Caro-Vega, Department of Infectious Diseases, National Institute of Medical
Sciences and Nutrition, Salvador Zubirán, Mexico City, Mexico

17.15–17.25Gender disparities in geriatric syndromes among people 50 years and older
receiving care for HIV-infection in Mexico (2012-2017)

Pablo Belaunzaran-Zamudio, Department of Infectious Diseases, National Institute
of Medical Sciences and Nutrition, Salvador Zubirán, Mexico City, Mexico

17.25–18.00Panel discussion 

18.00–18.45Welcome Reception, Scientific Posters and Exhibition

Day Two

09.00–10.30ViiV Industry Symposium

10.30–11.00Coffee, Scientific Posters and Exhibition

11.00–12.30HIV Prevention 2020 and Beyond: Progress, Challenges, and the Next Generation

11.00–11.15Universal Test and Treat and U=U: how much of an impact can it have
on slowing HIV spread?

Omar Sued, Fundación Huésped, Buenos Aires, Argentina

11.15–11.30Oral PrEP Implementation in Latin America: what have we learned
so far?

Andrea González-Rodríguez, HIV/AIDS City Programme,
Mexico City, Mexico

11.30–11.45Emerging approaches to expand PrEP access, uptake and adherence
Esper Kallas, University of of São Paulo, São Paulo, Brazil

11.45–12.00Next generation PrEP: Injections, implants and infrequent oral dosing
Kenneth Mayer, Medical Research Director, Fenway Health, Harvard Medical School
and Beth Israel Deaconess Hospital, Boston, MA, USA

12.00–12.10Breastfeeding practices and beliefs among postpartum mothers living with
HIV in Latin American and Caribbean countries: a systematic review

12.10–12.30Panel discussion


12.45–14.15MSD Industry Symposium


14.30–15.30Keynote Lectures: Hepatitis C: Where are the Patient

14.30-15.00Jürgen Rockstroh, University of Bonn, Bonn, Germany

15.00-15.30Natalia Laufer, INBIRS Institute (UBA-CONICET), Buenos Aires, Argentina

15.30–16.30Clinical Challenges in the Treatment of TB

15.30–15.45TB prevention: the case for Rifapentine

15.45–16.00Multi-drug resistant TB: new treatment options
Jean Pape, Center for Global Health, Division of Infectious Diseases, Weill Cornell
Medicine, New York, NY, USA and Les Centres GHESKIO, Port-au-Prince, Haïti

16.00–16.15Immunology in TB
María Florencia Quiroga, Department of Microbiology, Parasitology and Immunology,
University of Buenos Aires School of Medicine, Buenos Aires, Argentina

16.15–16.30Panel disucssion

16.30–17.00CROI Review
Roy Gulick, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA

17.00–17.30Coffee, Scientific Posters and Exhibition

17.30–19.00What Next After Hepatitis C?

17.30–17.45Hepatitis B and D: where is it and who does it effect in Latin America?
Mark Nelson, Chelsea & Westminster Hospital, London, UK

17.45–18.00Direct acting antiviral failures and how to treat
Jorge L Santana, University of Puerto Rico School of Medicine, San Juan, Puerto Rico

18.00–18.15NASH and NAFLD: what we know and how do we treat?
Esteban Gonzalez Ballerga, Hospital ‘José de San Martín’, University of
Buenos Aires, Buenos Aires, Argentina

18.15–18.25Oral Presentation

18.25–19.00Panel discussion

19.00–19.45Reception, Scientific Posters and Exhibition

Day Three

09.00–10.30Challenging Treatment Cases
Interactive Case Study Session in Collaboration with the International Antiviral
Society-USA (IAS-USA)
Moderator:Carlos del Rio, Department of Medicine, Division of Infectious
Diseases, Emory University School of Medicine, Atlanta, GA, USA

09.00–09.10Welcome and introduction
Carlos del Rio

09.10–09.35Case 1: What to start in women of reproductive age
Marcelo Losso,
Hospital JM Ramos Mejia, Buenos Aires and CICAL
Buenos Aires, Argentina

09.35–10.00Case 2: Virologically doing well but are there better options available?
Alicia Piñeirúa‐Menendez, Clinica Especializada Condesa Iztapalapa,
Mexico City, Mexico

10.00–10.25Case 3: Opportunistic infection with HIV
Claudia Cortes, University of Chile, Santiago, Chile

10.25–10.30Closing remarks
Carlos del Rio

10.30–11.00Coffee, Scientific Posters and Exhibition

11.00–12.45How Special are the Special Populations?

11.00–11.30Keynote Lecture: Transgender Population: Care and Hormone Therapy
Madeline B Deutsch, Clinical Family & Community Medicine, UCSF, San Francisco,

11.30–11.45Is there any difference between men and women with HIV?
Brenda Crabtree-Ramirez, Instituton Nacional de Ciencias Medicas y Nutricion
Salvador Zubiran, Mexico City, Mexico

11.45–12.00Are we addressing women’s HIV Prevention needs

12.00–12.15Paediatrics and HIV: what do we need to know?

12.15–12.25Transgender persons on PrEP in Brazil: who they are and how to scale up
their access to this HIV Combination Prevention technology
Alicia Kruger,
Department of Diseases of Chronic Conditions
and Sexually Transmitted Infections, Ministry of Health of Brazil, Brasilia, Brazil

12.25–12.45Panel discussion

12.45–13.30Lunch, Scientific Posters and Exhibition

13.30–15.002020 Milestones and Trends Towards Ending AIDS by 2030 in the Americas
In collaboration with the Pan American Health Organization (PAHO)

13.30–13.50Setting the scene
Massimo Ghidinelli, PAHO, Washington DC, USA

13.50–14.35Moderated panel discussion
Pedro Cahn, Fundación Huésped, Buenos Aires, Argentina
Shanti Singh-Anthony, Pan Carribean Partnership Against HIV and AIDS (PANCAP)
Greater Georgetown, Guyana

14.35–15.00Audience Q & A

15.00–15.10Closing Remarks
Juan Sierra-Madero, Institution Nacional de Ciencias Medicas y Nutricion Salvador
Zubiran, Mexico City, Mexico